0.7225
4.30%
-0.0325
Talphera Inc stock is traded at $0.7225, with a volume of 76,684.
It is down -4.30% in the last 24 hours and down -25.76% over the past month.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
See More
Previous Close:
$0.755
Open:
$0.745
24h Volume:
76,684
Relative Volume:
0.79
Market Cap:
$11.75M
Revenue:
$2.82M
Net Income/Loss:
$-14.20M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
$-15.13M
1W Performance:
+2.28%
1M Performance:
-25.76%
6M Performance:
-29.85%
1Y Performance:
+0.00%
Talphera Inc Stock (TLPH) Company Profile
Compare TLPH with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
TLPH
Talphera Inc
|
0.7225 | 11.75M | 2.82M | -14.20M | -15.13M | 0.00 |
ZTS
Zoetis Inc
|
176.74 | 80.59B | 9.15B | 2.43B | 2.31B | 4.92 |
HLN
Haleon Plc Adr
|
9.72 | 44.17B | 14.26B | 1.55B | 0 | 0.3327 |
TAK
Takeda Pharmaceutical Co Adr
|
13.57 | 42.61B | 30.27B | 1.93B | 3.45B | 0.444 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.57 | 18.77B | 16.77B | -959.00M | 1.37B | -2.00 |
VTRS
Viatris Inc
|
13.22 | 15.73B | 15.05B | -883.30M | 1.89B | 1.53 |
Talphera Inc Stock (TLPH) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-20-20 | Downgrade | Credit Suisse | Neutral → Underperform |
Nov-11-19 | Downgrade | Credit Suisse | Outperform → Neutral |
Aug-05-19 | Resumed | Credit Suisse | Outperform |
Jul-10-19 | Resumed | Credit Suisse | Outperform |
Apr-24-19 | Resumed | B. Riley FBR | Buy |
Feb-15-19 | Initiated | Credit Suisse | Outperform |
Oct-23-18 | Initiated | B. Riley FBR | Buy |
Oct-13-17 | Downgrade | Jefferies | Buy → Hold |
Oct-13-17 | Reiterated | RBC Capital Mkts | Outperform |
Jul-14-17 | Resumed | Jefferies | Buy |
Sep-15-16 | Reiterated | ROTH Capital | Buy |
Aug-05-16 | Downgrade | Stifel | Buy → Hold |
Oct-30-15 | Upgrade | Jefferies | Hold → Buy |
Oct-05-15 | Reiterated | ROTH Capital | Buy |
Sep-02-15 | Initiated | H.C. Wainwright | Buy |
Jul-10-15 | Resumed | ROTH Capital | Buy |
May-06-15 | Reiterated | Mizuho | Neutral |
May-05-15 | Reiterated | RBC Capital Mkts | Outperform |
Mar-10-15 | Reiterated | RBC Capital Mkts | Outperform |
Mar-09-15 | Downgrade | Mizuho | Buy → Neutral |
View All
Talphera Inc Stock (TLPH) Latest News
Talphera Third Quarter 2024 Earnings: US$0.13 loss per share (vs US$0.085 loss in 3Q 2023) - Yahoo Finance
Talphera (FRA:R5XA) Inventories, Raw Materials & Components : €0.00 Mil (As of Jun. 2024) - GuruFocus.com
Talphera Inc (TLPH) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial Challenges - Yahoo Finance
Talphera: Q3 Earnings Snapshot - mySA
Talphera Reports Q3 2024 Results and Study Progress - TipRanks
Talphera's Q3 Loss Widens to $3.4M as NEPHRO Trial Expands to New Sites | TLPH Stock News - StockTitan
Talphera Announces Third Quarter 2024 Financial Results and Provides Corporate Update - PR Newswire
An Overview of Talphera's Earnings - Benzinga
Talphera Sets Q3 2024 Earnings Call for November 13Key Financial Results Update | TLPH Stock News - StockTitan
Talphera, Inc. (NASDAQ:TLPH) Sees Large Decline in Short Interest - Defense World
Talphera to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit - Citizentribune
Talphera extends agreement deadline with Nantahala Management By Investing.com - Investing.com Australia
Talphera extends agreement deadline with Nantahala Management - Investing.com
Talphera to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Kilgore News Herald
Talphera CEO Vincent J. Angotti buys $7.6k in company stock - Investing.com
Credit Suisse gives an Underperform recommendation for Talphera Inc. (TLPH) - Knox Daily
TLPH Stock Earnings: Talphera Beats EPS for Q2 2024 - MSN
Talphera starts key trial for anticoagulant nafamostat - Investing.com India
Talphera starts key trial for anticoagulant nafamostat By Investing.com - Investing.com Canada
Talphera Announces First Patient Enrolled in the Registrational Trial Evaluating Nafamostat for Anticoagulation of the Extracorporeal Circuit - PR Newswire
Talphera First Half 2024 Earnings: US$0.31 loss per share (vs US$0.40 loss in 1H 2023) - Yahoo Finance
Talphera Inc (TLPH) Q2 2024 Earnings Call Transcript Highlights: Strategic Advancements and Financial Adjustments - GuruFocus.com
Talphera: Q2 Earnings Snapshot - San Antonio Express-News
Talphera Announces First Quarter 2024 Financial Results and Provides Corporate Update - Longview News-Journal
Talphera, Inc. (NASDAQ:TLPH) Q2 2024 Earnings Call Transcript - MSN
Talphera Announces CMO Retirement and Successor Appointment - TipRanks
Talphera Announces Second Quarter 2024 Financial Results and Provides Corporate Update - PR Newswire
Comparing Talphera (NASDAQ:TLPH) and Altimmune (NASDAQ:ALT) - Defense World
Talphera (TLPH) to Release Earnings on Wednesday - Defense World
Talphera to Host Second Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, August 14, 2024 - Longview News-Journal
Talphera, Inc. (NASDAQ:TLPH) Short Interest Down 20.8% in July - Defense World
TLPH (Talphera) Cash-to-Debt : No Debt - GuruFocus.com
Short Interest in Talphera, Inc. (NASDAQ:TLPH) Drops By 16.9% - Defense World
Talphera secures shareholder nod for executive compensation plans By Investing.com - Investing.com India
Talphera Shareholders Affirm Leadership and Financial Strategy - TipRanks
Atlassian's president sells shares worth $121600 By Investing.com - Investing.com
UCB shares target raised on strong product launches, rated Overweight By Investing.com - Investing.com Australia
Talphera Inc. [TLPH] Investment Guide: What You Need to Know – Knox Daily - Knox Daily
Quarterly Snapshot: Quick and Current Ratios for Talphera Inc. (TLPH) – DWinneX - The Dwinnex
Talphera Inc. (TLPH) Stock: A Year of Highs and Lows in the Market - The InvestChronicle
Talphera CEO Angotti buys shares worth $9856 By Investing.com - Investing.com Canada
Talphera CEO Angotti buys shares worth $9856 - Investing.com India
Talphera Inc Stock (TLPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Talphera Inc Stock (TLPH) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Angotti Vincent J. | CHIEF EXECUTIVE OFFICER |
Jun 13 '24 |
Buy |
0.97 |
4,570 |
4,438 |
179,502 |
Angotti Vincent J. | CHIEF EXECUTIVE OFFICER |
Jun 12 '24 |
Buy |
0.97 |
4,126 |
4,013 |
174,932 |
Angotti Vincent J. | CHIEF EXECUTIVE OFFICER |
Jun 14 '24 |
Buy |
1.08 |
1,304 |
1,404 |
180,806 |
Angotti Vincent J. | Chief Executive Officer |
Dec 13 '23 |
Buy |
0.73 |
10,000 |
7,268 |
101,805 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):